Literature DB >> 26374897

The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E.

Charles C Bailey1, Lindsey B DeVaux2, Michael Farzan2.   

Abstract

The triggering receptor expressed on myeloid cells 2 (TREM2) is an Ig-like V-type receptor expressed by populations of myeloid cells in the central nervous system and periphery. Loss-of-function mutations in TREM2 cause a progressive, fatal neurodegenerative disorder called Nasu-Hakola disease. In addition, a TREM2 R47H coding variant was recently identified as a risk factor for late-onset Alzheimer disease. TREM2 binds various polyanionic molecules but no specific protein ligands have been identified. Here we show that TREM2 specifically binds apolipoprotein E, a well established participant in Alzheimer disease. TREM2-Ig fusions efficiently precipitate ApoE from cerebrospinal fluid and serum. TREM2 also binds recombinant ApoE in solution and immobilized ApoE as detected by ELISA. Furthermore, the Alzheimer disease-associated R47H mutation, and other artificial mutations introduced in the same location, markedly reduced the affinity of TREM2 for ApoE. These findings reveal a link between two Alzheimer disease risk factors and may provide important clues to the pathogenesis of Nasu-Hakola disease and other neurodegenerative disorders.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; Nasu-Hakola disease; PLOSL; TREM2; apolipoprotein E (ApoE); genetic polymorphism; high-density lipoprotein (HDL); myeloid cell; neurodegenerative disease

Mesh:

Substances:

Year:  2015        PMID: 26374897      PMCID: PMC4646256          DOI: 10.1074/jbc.M115.677286

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia.

Authors:  Elise Cuyvers; Karolien Bettens; Stéphanie Philtjens; Tim Van Langenhove; Ilse Gijselinck; Julie van der Zee; Sebastiaan Engelborghs; Mathieu Vandenbulcke; Jasper Van Dongen; Nathalie Geerts; Githa Maes; Maria Mattheijssens; Karin Peeters; Patrick Cras; Rik Vandenberghe; Peter P De Deyn; Christine Van Broeckhoven; Marc Cruts; Kristel Sleegers
Journal:  Neurobiol Aging       Date:  2013-10-09       Impact factor: 4.673

2.  Specific lipid recognition is a general feature of CD300 and TREM molecules.

Authors:  John P Cannon; Marci O'Driscoll; Gary W Litman
Journal:  Immunogenetics       Date:  2011-07-29       Impact factor: 2.846

3.  Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage.

Authors:  Patrick Wunderlich; Konstantin Glebov; Nadja Kemmerling; Nguyen T Tien; Harald Neumann; Jochen Walter
Journal:  J Biol Chem       Date:  2013-09-27       Impact factor: 5.157

4.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

5.  Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement.

Authors:  Rita João Guerreiro; Ebba Lohmann; José Miguel Brás; Jesse Raphael Gibbs; Jonathan D Rohrer; Nicole Gurunlian; Burcu Dursun; Basar Bilgic; Hasmet Hanagasi; Hakan Gurvit; Murat Emre; Andrew Singleton; John Hardy
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

6.  Mutations in TREM2 lead to pure early-onset dementia without bone cysts.

Authors:  Eliane Chouery; Valérie Delague; Anne Bergougnoux; Salam Koussa; Jean-Louis Serre; André Mégarbané
Journal:  Hum Mutat       Date:  2008-09       Impact factor: 4.878

7.  TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells.

Authors:  Norimoto Kobayashi; Piia Karisola; Victor Peña-Cruz; David M Dorfman; Masahisa Jinushi; Sarah E Umetsu; Manish J Butte; Haruo Nagumo; Irene Chernova; Baogong Zhu; Arlene H Sharpe; Susumu Ito; Glenn Dranoff; Gerardo G Kaplan; Jose M Casasnovas; Dale T Umetsu; Rosemarie H Dekruyff; Gordon J Freeman
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

8.  A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia.

Authors:  Christine L Hsieh; Maya Koike; Steve C Spusta; Erene C Niemi; Midori Yenari; Mary C Nakamura; William E Seaman
Journal:  J Neurochem       Date:  2009-03-19       Impact factor: 5.372

9.  TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease.

Authors:  Sruti Rayaprolu; Bianca Mullen; Matt Baker; Timothy Lynch; Elizabeth Finger; William W Seeley; Kimmo J Hatanpaa; Catherine Lomen-Hoerth; Andrew Kertesz; Eileen H Bigio; Carol Lippa; Keith A Josephs; David S Knopman; Charles L White; Richard Caselli; Ian R Mackenzie; Bruce L Miller; Magdalena Boczarska-Jedynak; Grzegorz Opala; Anna Krygowska-Wajs; Maria Barcikowska; Steven G Younkin; Ronald C Petersen; Nilüfer Ertekin-Taner; Ryan J Uitti; James F Meschia; Kevin B Boylan; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers; Owen A Ross
Journal:  Mol Neurodegener       Date:  2013-06-21       Impact factor: 14.195

10.  TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis.

Authors:  Kazuya Takahashi; Marco Prinz; Massimiliano Stagi; Olga Chechneva; Harald Neumann
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

View more
  121 in total

1.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Authors:  Laura Piccio; Yuetiva Deming; Jorge L Del-Águila; Laura Ghezzi; David M Holtzman; Anne M Fagan; Chiara Fenoglio; Daniela Galimberti; Barbara Borroni; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2016-01-11       Impact factor: 17.088

Review 2.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 3.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases.

Authors:  Tao Gong; Lei Liu; Wei Jiang; Rongbin Zhou
Journal:  Nat Rev Immunol       Date:  2019-09-26       Impact factor: 53.106

4.  Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2.

Authors:  Athena Sudom; Santosh Talreja; Jean Danao; Eric Bragg; Rob Kegel; Xiaoshan Min; Jason Richardson; Zhongqi Zhang; Nikolai Sharkov; Edoardo Marcora; Steve Thibault; Jodi Bradley; Steve Wood; Ai-Ching Lim; Hang Chen; Songli Wang; Ian N Foltz; Shilpa Sambashivan; Zhulun Wang
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

5.  TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.

Authors:  Tyler K Ulland; Wilbur M Song; Stanley Ching-Cheng Huang; Jason D Ulrich; Alexey Sergushichev; Wandy L Beatty; Alexander A Loboda; Yingyue Zhou; Nigel J Cairns; Amal Kambal; Ekaterina Loginicheva; Susan Gilfillan; Marina Cella; Herbert W Virgin; Emil R Unanue; Yaming Wang; Maxim N Artyomov; David M Holtzman; Marco Colonna
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

Review 6.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 7.  Untangling Genetic Risk for Alzheimer's Disease.

Authors:  Anna A Pimenova; Towfique Raj; Alison M Goate
Journal:  Biol Psychiatry       Date:  2017-05-22       Impact factor: 13.382

Review 8.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

9.  Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation.

Authors:  Wilbur Song; Basavaraj Hooli; Kristina Mullin; Sheng Chih Jin; Marina Cella; Tyler K Ulland; Yaming Wang; Rudolph E Tanzi; Marco Colonna
Journal:  Alzheimers Dement       Date:  2016-08-09       Impact factor: 21.566

Review 10.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.